The recent inclusion of interchangeable use of plasma and CSF GFAP as a marker of inflammation (category ‘I’) in the Alzheimer’s Association Workgroup criteria for diagnosis and staging of Alzheimer’s disease showcases its suggested diagnostic potential [4]. The gene discussed is GFAP; the disease is early-onset autosomal dominant Alzheimer disease.